Serum interferon-alpha level in first degree relatives of systemic lupus erythematosus patients: Correlation with autoantibodies titers

Egyptian Journal of Medical Human Genetics

Volumn 12, Issue 2, 2011, Pages 139-146

  Shahin, Dina ^a   El Refaey, Ahmed M ^a   El Hawary, Amany K ^a   Salam, Adel Abdel ^a   Machaly, Sherine ^a   Abousamra, Nashwa ^a   El farahaty, Reham M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Autoantibodies; First degree relatives; Interferon ; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC CORRELATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MALE; POPULATION GENETICS; PROTEIN BLOOD LEVEL; RELATIVE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84886746691     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2011.06.009     Document Type: Article

References (50)

1. Mok C.C., Lau C.S. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003, 56:481-490.
2. Ruiz-Irastorza G., Khamashta M.A., Castellino G., Hughes G.R. Systemic lupus erythematosus. Lancet 2001, 357:1027-1032.
3. Rönnblom L., Alm G.V. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001, 22:427-431.
4. Pascual V., Allantaz F., Patel P., Palucka K., Chaussabel D., Banchereau J. How the study of children with rheumatic diseases identified interferon alpha and interleukin 1 as novel therapeutic targets. Immunol Rev 2008, 223:39-59.
5. Lundsgaard D., Jacobsen S., Pedersen I.L., Hummelshøj L., Poulsen L.K., Keller P., et al. Interferon-α correlates positively with disease severity in Danish patients with SLE. Cytokine 2009, 48:95. (abstract, doi:10.1016/j.cyto.2009.07.398).
6. Rönnblom L. Potential role of IFNα in adult lupus. Arthritis Res Therapy 2010, 12:S3.
7. Kanayama K., Negoro N., Okamura M., Takeda T., Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987, 70:562-569.
8. Ytterberg S.R., Schnitzer T.J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982, 25:401-406.
9. Bengtsson A.A., Sturfelt G., Truedsson L., Blomberg J., Alm G., Vallin H., Rönnblom L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000, 9:664-671.
10. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
11. Niewold T.B. Interferon alpha-induced lupus proof of principle. J Clin Rheumatol 2008, 14:131-132.
12. Raanani P., Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002, 107:133-144.
13. Niewold T.B., Swedler W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005, 24:178-181.
14. Rönnblom L., Alm G.V. The natural interferon-α producing cells in systemic lupus erythematosus. Human Immunol 2002, 63:1181-1193.
15. Ioannou Y., Isenberg D.A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000, 43:1431-1442.
16. Devendra D., Eisenbarth G.S. Interferon alpha- a potential link in the pathogenesis of viral induced type 1 diabetes and autoimmunity. Clinical Immunol 2004, 111:225-233.
17. Crow M.K. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Therapy 2010, 12:S5.
18. Scofield R.H., Bruner G.R., Harley J.B., Namjou B. Autoimmune thyroid disease is associated with a diagnosis of secondary Sjogren's syndrome in familial systemic lupus. Ann Rheum Dis 2007, 66:410-413.
19. Tsao B.P., Grossman J.M., Riemekasten G., Strong N., Kalsi J., Wallace D.J., et al. Familiality and co-occurrence of clinical features of systemic lupus erythematosus. Arthritis Rheum 2002, 46:2678-2685.
20. Wandstrat A.E., Carr-Johnson F., Branch V., Gray H., Fairhurst A.M., Reimold A., et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmunity 2006, 27:153-1560.
21. Shoenfeld Y., Slor H., Shafrir S., Krause I., Granados J., Villarreal G.M., et al. Diversity and pattern of inheritance of autoantibodies in families with multiple cases of systemic lupus erythematosus. Ann Rheum Dis 1992, 51:611-618.
22. Navarra SV, Ishimori ML, Uy EA, Hamijoyo L, Sama J, James JA et al. studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first- degree relatives. Lupus 2010. [Epub ahead of print].
23. Niewold T.B., Hua J., Lehman T.J.A., Harley J.B., Crow M.K. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007, 8:492-502.
24. Li Q.Z., Karp D.R., Quan J., Branch V.K., Zhou J., Lian Y., Chong B.F., Wakeland E.K., Olsen N.J. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011, 13:R38. [Epub ahead of print].
25. Scofield R.H. Autoantibodies as predictors of disease. Lancet 2004, 363:1544-1546.
26. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
27. Swaak A.J., van de Brink H., Smeenk R.J., Manger K., Kalden J.R., Tosi S. Study group on incomplete SLE and SLE with disease duration longer than 10years. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology 2001, 40:89-94.
28. Aly T., Devendra D., Barker J., Liu E., Yu L., Eisenbarth G.S. Heterophile antibodies masquerade as interferon-α in subjects with new-onset type 1 diabetes. Diabetes Care 2004, 27:1205-1206.
29. Sisó A., Ramos-Casals M., Bové A., Brito-Zerón P., Soria N., Muñoz S., et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008, 17:281-288.
30. Bauer J.W., Petri M., Batliwalla F.M., Koeuth T., Wilson J., Slattery C., et al. Interferon- regulated chemikines as biomarkers of systemic lupus erythematosus disease activity. Arthritis Rheum 2009, 60:3098-3107.
31. Pascual V., Farkas L., Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006, 18:676-682.
32. Maas K., Chen H., Shyr Y., Olsen N.J., Aune T. shared gene expression profiles in individuals with autoimmune disease and unaffected first degree reletives of individuals with autoimmune disease. Human Mol Gene 2005, 14:1305-1314.
33. Pascual V., Banchereau J., Palucka A.K. The central role of dendritic cells and interferon-α in SLE. Curr Opin Rheumatol 2003, 15:548-556.
34. Cederblad B., Blomberg S., Vallin H., Perers A., Alm G.V., Rönnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 1998, 11:465-470.
35. Vallin H., Blomberg S., Alm G.V., Cedarblad B., Rönnblom L. patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon- alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999, 115:196-202.
36. Steup-Beekman G.M., Steens S.C.A., van Buchem M.A., Huizinga T.W.J. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007, 16:329-334.
37. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., Harley J.B. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
38. Shmerling R.H. Autoantibodies in systemic lupus erythematosus- there before you know it. N Engl J Med 2003, 349:1499-1500.
39. Li Q.Z., Zhou J., Lian Y., Zhang B., Branch V.K., Carr-Jonson F., Karp D.R., et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol 2010, 159:281-291.
40. Bauer J.W., Baechler E.C., Petri M., Batliwalla F.M., Crawford D., Ortmann W.A., Espe K.J., Li W., Patel D.D., Gregersen P.K., Behrens T.W. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006, 3:e491.
41. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., Crow M.K. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematous patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503.
42. Wenzel J., Wörenkämper E., Freutel S., Henze S., Haller O., Bieber T., Tüting T. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005, 205:435-442.
43. Chakrabarti D., Hultgren B., Stewart T.A. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 1996, 157:522-528.
44. Bauer J.W., Petri M., Batliwalla F.M., Koeuth T., Wilson J., Slattery C., Panoskaltsis-Mortari A., Gregersen P.K., Behrens T.W., Baechler E.C. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009, 60:3098-3107.
45. Wang J., Lin Q., Langston H., Cooper M.D. Resident bone marrow macrophages produce type 1 interferons that can selectively inhibit interleukin-7-driven growth of B lineage cells. Immunity 1995, 3:475-484.
46. Lin Q., Dong C., Cooper M.D. Impairment of T and B cell development by treatment with a type I interferon. J Exp Med 1998, 187(1):79-87.
47. Baechler E.C., Gregersen P.K., Behrens T.W. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004, 16(6):801-807.
48. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood 2003, 197(6):711-723.
49. Niewold T.B., Adler J.E., Glenn S.B., Lehman T.J., Harley J.B., Crow M.K. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 2008, 58(7):2113-2119.
50. Tsao B.P., Grossman J.M., Riemekasten G., Strong N., Kalsi J., Wallace D.J., Chen C.J., Lau C.S., Ginzler E.M., Goldstein R., Kalunian K.C., Harley J.B., Arnett F.C., Hahn B.H., Cantor R.M. Familiality and co-occurrence of clinical features of systemic lupus erythematosus. Arthritis Rheum 2002, 46(10):2678-2685.